Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LoneStar Heart Inc.

Addressing heart failure with an injectable biopolymer

This article was originally published in Start Up

Executive Summary

LoneStar Heart's injectable biopolymer Algisyl-LVR represents a new advanced HF treatment strategy based on a medically accepted principle that a reduction in muscle tension and wall stress of the dilated heart will improve its function. The company, which originally envisioned Algisyl-LVR as a carrier for targeted delivery of biologics, drugs, or stem cells, discovered in animal studies that use of the biopolymer by itself had a profound effect on improving the mechanics of the heart.

You may also be interested in...



Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant

The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.

What’s Next? Five Things To Look Out For In December

Generics Bulletin previews the most noteworthy and anticipated events for December 2023.

Member States Want Action Over High-Risk IVDs And Eudamed Medical Device Database

After some 10 years of the implementation of the EU’s Medical Device and IVD Regulations being an annual agenda item at December Council of the EU meetings, the scale of problems remains the same.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel